Table of Contents Author Guidelines Submit a Manuscript
International Journal of Peptides
Volume 2015 (2015), Article ID 537508, 8 pages
http://dx.doi.org/10.1155/2015/537508
Research Article

High Proteolytic Resistance of Spider-Derived Inhibitor Cystine Knots

1Laboratory for Drug Discovery and Glycoscience and Glycotechnology Research Group, Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology (AIST), AIST Tsukuba Central 2, 1-1-1 Umezono, Tsukuba, Ibaraki 305-8568, Japan
2United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu, Gifu Prefecture 501-1193, Japan

Received 25 September 2015; Revised 30 November 2015; Accepted 9 December 2015

Academic Editor: Eva Ekblad

Copyright © 2015 Kyoko Kikuchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Bernkop-Schnürch, “The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins,” Journal of Controlled Release, vol. 52, no. 1-2, pp. 1–16, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. B. F. Choonara, Y. E. Choonara, P. Kumar, D. Bijukumar, L. C. du Toit, and V. Pillay, “A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules,” Biotechnology Advances, vol. 32, no. 7, pp. 1269–1282, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. V. K. Pawar, J. G. Meher, Y. Singh, M. Chaurasia, B. S. Reddy, and M. K. Chourasia, “Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives,” Journal of Controlled Release, vol. 196, pp. 168–183, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Werle and A. Bernkop-Schnürch, “Strategies to improve plasma half life time of peptide and protein drugs,” Amino Acids, vol. 30, no. 4, pp. 351–367, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Fosgerau and T. Hoffmann, “Peptide therapeutics: current status and future directions,” Drug Discovery Today, vol. 20, no. 1, pp. 122–128, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. C. I. Schroeder and D. J. Craik, “Therapeutic potential of conopeptides,” Future Medicinal Chemistry, vol. 4, no. 10, pp. 1243–1255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Truong-Le, P. M. Lovalenti, and A. M. Abdul-Fattah, “Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems,” Advanced Drug Delivery Reviews, vol. 93, pp. 95–108, 2015. View at Publisher · View at Google Scholar
  8. G. F. King, “Venoms as a platform for human drugs: translating toxins into therapeutics,” Expert Opinion on Biological Therapy, vol. 11, no. 11, pp. 1469–1484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. Clark, H. Fischer, L. Dempster et al., “Engineering stable peptide toxins by means of backbone cyclization: stabilization of the α-conotoxin MII,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 13767–13772, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. Armishaw, N. L. Daly, S. T. Nevin, D. J. Adams, D. J. Craik, and P. F. Alewood, “α-selenoconotoxins, a new class of potent α7 neuronal nicotinic receptor antagonists,” The Journal of Biological Chemistry, vol. 281, no. 20, pp. 14136–14143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Colgrave and D. J. Craik, “Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot,” Biochemistry, vol. 43, no. 20, pp. 5965–5975, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Craik, N. L. Daly, and C. Waine, “The cystine knot motif in toxins and implications for drug design,” Toxicon, vol. 39, no. 1, pp. 43–60, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Heitz, O. Avrutina, D. Le-Nguyen et al., “Knottin cyclization: impact on structure and dynamics,” BMC Structural Biology, vol. 8, article 54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Kolmar, “Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins,” Current Opinion in Pharmacology, vol. 9, no. 5, pp. 608–614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Reinwarth, D. Nasu, H. Kolmar, and O. Avrutina, “Chemical synthesis, backbone cyclization and oxidative folding of cystine-knot peptides—promising scaffolds for applications in drug design,” Molecules, vol. 17, no. 11, pp. 12533–12552, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. C. P. Sommerhoff, O. Avrutina, H.-U. Schmoldt, D. Gabrijelcic-Geiger, U. Diederichsen, and H. Kolmar, “Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase β,” Journal of Molecular Biology, vol. 395, no. 1, pp. 167–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. H. G. Park, S. S. Kyung, K. S. Lee et al., “Dual function of a bee (Apis cerana) inhibitor cysteine knot peptide that acts as an antifungal peptide and insecticidal venom toxin,” Developmental and Comparative Immunology, vol. 47, no. 2, pp. 247–253, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Gao, C. Tian, and S. Zhu, “Inducible antibacterial response of scorpion venom gland,” Peptides, vol. 28, no. 12, pp. 2299–2305, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Pimentel, S.-J. Choi, B. Chagot, C. Guette, J.-M. Camadro, and H. Darbon, “Solution structure of PcFK1, a spider peptide active against Plasmodium falciparum,” Protein Science, vol. 15, no. 3, pp. 628–634, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Kimura, S. Ono, and T. Kubo, “Molecular cloning and sequence analysis of the cDNAS encoding toxin-like peptides from the venom glands of tarantula Grammostola rosea,” International Journal of Peptides, vol. 2012, Article ID 731293, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Ono, T. Kimura, and T. Kubo, “Characterization of voltage-dependent calcium channel blocking peptides from the venom of the tarantula Grammostola rosea,” Toxicon, vol. 58, no. 3, pp. 265–276, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. J. Smith, V. Herzig, G. F. King, and P. F. Alewood, “The insecticidal potential of venom peptides,” Cellular and Molecular Life Sciences, vol. 70, no. 19, pp. 3665–3693, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Dworakowska and K. Dołowy, “Ion channels-related diseases,” Acta Biochimica Polonica, vol. 47, no. 3, pp. 685–703, 2000. View at Google Scholar · View at Scopus
  24. D. Conte Camerino, D. Tricarico, and J.-F. Desaphy, “Ion channel pharmacology,” Neurotherapeutics, vol. 4, no. 2, pp. 184–198, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. C. Cannon, “Physiologic principles underlying ion channelopathies,” Neurotherapeutics, vol. 4, no. 2, pp. 174–183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Mathie, “Ion channels as novel therapeutic targets in the treatment of pain,” Journal of Pharmacy and Pharmacology, vol. 62, no. 9, pp. 1089–1095, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. N. J. Saez, S. Senff, J. E. Jensen et al., “Spider-venom peptides as therapeutics,” Toxins, vol. 2, no. 12, pp. 2851–2871, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. T.-J. Fu, U. R. Abbott, and C. Hatzos, “Digestibility of food allergens and nonallergenic proteins in simulated gastric fluid and simulated intestinal fluid—a comparative study,” Journal of Agricultural and Food Chemistry, vol. 50, no. 24, pp. 7154–7160, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Werle, T. Schmitz, H.-L. Huang, A. Wentzel, H. Kolmar, and A. Bernkop-Schnürch, “The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery,” Journal of Drug Targeting, vol. 14, no. 3, pp. 137–146, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Li, J. J. Bowling, M. Su et al., “Asteropsins B-D, sponge-derived knottins with potential utility as a novel scaffold for oral peptide drugs,” Biochimica et Biophysica Acta—General Subjects, vol. 1840, no. 3, pp. 977–984, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. R. E. Middleton, V. A. Warren, R. L. Kraus et al., “Two tarantula peptides inhibit activation of multiple sodium channels,” Biochemistry, vol. 41, no. 50, pp. 14734–14747, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. B. T. Priest, K. M. Blumenthal, J. J. Smith, V. A. Warren, and M. M. Smith, “ProTx-I and ProTx-II: gating modifiers of voltage-gated sodium channels,” Toxicon, vol. 49, no. 2, pp. 194–201, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. K. L. Ostrow, A. Mammoser, T. Suchyna et al., “cDNA sequence and in vitro folding of GsMTx4, a specific peptide inhibitor of mechanosensitive channels,” Toxicon, vol. 42, no. 3, pp. 263–274, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. T. M. Suchyna, J. H. Johnson, K. Hamer et al., “Identification of a peptide toxin from Grammostola spatulata spider venom that blocks cation-selective stretch-activated channels,” Journal of General Physiology, vol. 115, no. 5, pp. 583–598, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. J. H. Park, K. P. Carlin, G. Wu et al., “Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels,” Journal of Medicinal Chemistry, vol. 57, no. 15, pp. 6623–6631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Werle, K. Kafedjiiski, H. Kolmar, and A. Bernkop-Schnürch, “Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration,” International Journal of Pharmaceutics, vol. 332, no. 1-2, pp. 72–79, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Werle, H. Kolmar, R. Albrecht, and A. Bernkop-Schnürch, “Characterisation of the barrier caused by luminally secreted gastro-intestinal proteolytic enzymes for two novel cystine-knot microproteins,” Amino Acids, vol. 35, no. 1, pp. 195–200, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. W. A. Schmalhofer, J. Calhoun, R. Burrows et al., “ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors,” Molecular Pharmacology, vol. 74, no. 5, pp. 1476–1484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. S. J. Moore, C. L. Leung, H. K. Norton, and J. R. Cochran, “Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging,” PLoS ONE, vol. 8, no. 4, Article ID e60498, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. R. B. Shah, F. Ahsan, and M. A. Khan, “Oral delivery of proteins: progress and prognostication,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 19, no. 2, pp. 135–169, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. J. F. Woodley, “Enzymatic barriers for GI peptide and protein delivery,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 11, no. 2-3, pp. 61–95, 1994. View at Google Scholar · View at Scopus
  42. D. Guggi, A. H. Krauland, and A. Bernkop-Schnürch, “Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin,” Journal of Controlled Release, vol. 92, no. 1-2, pp. 125–135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. R. H. Kimura, Z. Cheng, S. S. Gambhir, and J. R. Cochran, “Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects,” Cancer Research, vol. 69, no. 6, pp. 2435–2442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. P. Silverman, A. M. Levin, J. L. Lahti, and J. R. Cochran, “Engineered cystine-knot peptides that bind αvβ3 integrin with antibody-like affinities,” Journal of Molecular Biology, vol. 385, no. 4, pp. 1064–1075, 2009. View at Publisher · View at Google Scholar
  45. C. Souriau, L. Chiche, R. Irving, and P. Hudson, “New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold,” Biochemistry, vol. 44, no. 19, pp. 7143–7155, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Stricher, C.-C. Huang, A. Descours et al., “Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein,” Journal of Molecular Biology, vol. 382, no. 2, pp. 510–524, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Glotzbach, M. Reinwarth, N. Weber et al., “Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1,” PLoS ONE, vol. 8, Article ID e76956, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Kubo, S. Ono, T. Kimura et al., “Random peptide library based on spider neurotoxin, and utilization of the library in in vitro evolution derected to GPCR ligands,” Toxicon, vol. 60, p. 113, 2012. View at Google Scholar